New York, December 8 (IANS). A global clinical trial led by an Indian-origin researcher has revealed that it may improve the survival rate of patients with common childhood leukemia.
B-cell acute lymphoblastic leukemia (B-ALL) is the most common cancer in children.
The Children’s Oncology Group’s clinical trial, conducted by scientists at The Hospital for Sick Children (SickKids) and Seattle Children’s Hospital, has shown promising results. This trial included more than 200 sites in four countries.
The findings, published in the New England Journal of Medicine, showed that people who received both chemotherapy and blinatumomab (an immunotherapy used for children with B-ALL) had a 61 percent lower risk of B-ALL relapse or death. Percentage decreased.
Study co-leader Dr. Sumit Gupta, oncologist and associate scientist in the Child Health Evaluative Sciences Program at SickKids, said, “These important data showing significant improvements in disease-free survival for nearly all children with newly diagnosed B-ALL provide tremendous clinical insight.” “Ready to provide benefits.”
“This is changing the standard of care for children with B-ALL around the world,” Gupta said.
Unlike chemotherapy, immunotherapy, like blinatumomab, uses the body’s own immune system to fight cancer by teaching the immune system to target cancer cells.
The study showed that the disease-free survival rate increased to 97.5 percent after three years for children with average risk of disease relapse, compared with 90 percent with chemotherapy alone.
In children who were at high risk of disease relapse, giving blinatumomab along with chemotherapy increased the disease-free survival rate from 85 percent to 94 percent.
“These findings highlight the progress made with the use of blinatumomab in disease relapse prevention and highlight its role in current therapeutic strategies,” said Dr. Rachel Rau, a pediatric hematologist and oncologist at Seattle Children’s Hospital who co-led the study. stands by.”
The findings included 1,440 children from Canada, the US, Australia and New Zealand.
“This new combination treatment is going to become the new standard of care for these patients, potentially saving many lives and reducing the fear and health effects associated with disease relapse,” said Gupta, an associate professor at the University of Toronto. Will come.”
–IANS
MKS/AS
